Glioblastoma Multiforme Treatment Market Size Report 2034 | Genentech, Merck, Daiichi Sankyo, VBL Therapeutics, Diffusion Pharmaceuticals Bayer, MedImmune, DNAtrix

DelveInsight's "Glioblastoma Multiforme Market Insight, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of GBM, historical and forecasted epidemiology as well as the GBM market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Glioblastoma Multiforme Market with DelveInsight's In-Depth Report @ Glioblastoma Multiforme Market Size- https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Glioblastoma Multiforme Market Report
• In February 2025:- Stemline Therapeutics Inc.:- This is a multicenter, open-label Phase 1/2 study evaluating the efficacy and safety of SL-701 as a treatment for recurrent GBM, divided into 2 stages. Seventy-four (74) participants were treated in the study, 46 in Stage 1 and 28 in Stage 2, men and women at least 18 years of age, all of whom showed unequivocal evidence of either a first tumor recurrence or progression during or following an initial treatment regimen before enrollment in this study. At least 54 of the 74 treated participants had measurable disease based on contrast-enhanced magnetic resonance imaging or computed tomography scans.
• Among the 7MM, the US accounted for approximately 41%, EU4 and the UK for 51%, and Japan for 8% of the total incident cases of GBM in 2023.
• In the EU4 and the UK, in 2023, the maximum number of incident cases according to the histological classification was for glioblastoma with approximately 17,550 cases while the lowest incident cases were of giant cell glioblastoma type with approximately 150 cases, which are expected to increase by 2034.
• In Japan, in 2023, the highest number of cases in the targeted therapy pool was for first-line treatments, with 2,690 cases, followed by second-line and above treatments with 1,365 cases.
• As per the DelveInsight estimates, it has been found that the primary site of GBM included maximum cases at the parietal site, while the minimum number of cases were found in unknown and other sites. This trend is evident across all the 7MM countries for the study period.
• The leading Glioblastoma Multiforme Companies such as Genentech, Merck, Daiichi Sankyo, VBL Therapeutics, Diffusion Pharmaceuticals Bayer, MedImmune, DNAtrix, Chimerix, Karyopharm Therapeutics, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Kintara Therapeutics, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, Treovir, Istari Oncology, and others.
• Promising Glioblastoma Multiforme Pipeline Therapies such as Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, LAM561 (2-OHOA), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, VAL-083 (dianhydrogalactitol), MDNA55, Paxalisib (GDC-0084), Temferon, EO2401, INO-5401 + INO-9012 + LIBTAYO (cemiplimab), Delytact (Teserpaturev/DS-1647), TAFINLAR + MEKINIST, VBI-1901, and others.

Stay ahead in the Glioblastoma Multiforme Therapeutics Market with DelveInsight's Strategic Report @ Glioblastoma Multiforme Market Outlook - https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glioblastoma Multiforme Epidemiology Segmentation in the 7MM
• Total Glioblastoma Multiforme Incident Population
• Glioblastoma Multiforme Gender-specific Incidence Cases
• Glioblastoma Multiforme Type-specific Incidence Cases
• Glioblastoma Multiforme Incident Cases based on Primary Site
• Glioblastoma Multiforme Age-specific Incidence Cases
• Incident Cases Based on Histologic Classification of Glioblastoma Multiforme Tumor
• Unmethylation of the MGMT Gene Promoter Cases,
• BRAF V600E Mutation Cases
• Line-wise Treated Pool

Download the report to understand which factors are driving Glioblastoma Multiforme epidemiology trends @ Glioblastoma Multiforme Prevalence- https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glioblastoma Multiforme Marketed Drugs

• AVASTIN (bevacizumab): Roche (Genentech)
AVASTIN is a recombinant humanized monoclonal IgG1 antibody, which acts as an angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). It binds to the VEGF with its receptors VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. This helps reduce VEGF activity and regress the vascularization of tumors, normalizing the tumor vasculature and inhibiting the formation of new tumor vasculature, thereby preventing tumor growth. VEGF is a chemical signal that stimulates angiogenesis in various diseases, especially cancer.

• TEMODAR/TEMODAL (temozolomide): Merck
The active pharmaceutical ingredient in TEMODAR/TEMODAL is an imidazotetrazine derivative of the alkylating agent dacarbazine. It is used for treating several brain cancer forms, e.g., as a second-line treatment for astrocytoma and a first-line treatment for GBM. The therapeutic benefit of TEMODAR is its ability to alkylate/methylate DNA. This alkylation/methylation destroys the DNA and triggers the death of the tumor cells. TEMODAR targets tumoral tissues selectively; it has an anti-neoplastic effect; it has minimum influence on adjacent brain tissues; it has no severe systemic toxicity; and it is eliminated rapidly.

Glioblastoma Multiforme Emerging Drugs

• DCVax-L: Northwest Biotherapeutics and Advent BioServices
DCVax-L is a fully personalized immune therapy made from a patient's immune cells (dendritic cells) and antigens (biomarkers) from a sample of the patient's tumor. DCVax-L is expected to be used for any solid tumor cancers in situations where the patient has their tumor surgically removed as part of standard care. DCVax -L is administered to the patient through a simple intradermal injection in the upper arm, similar to a flu shot. The dendritic cells then convey the tumor biomarker information to the rest of the immune system agents (T cells, B cells, and others) as "marching orders," and the immune system agents fan out through the body, searching for anything with these biomarkers and attacking it.

• TVI-Brain-1: TVAX Biomedical
TVI-Brain-1 is a patented vaccine-enhanced adoptive T-cell therapy (VACT) of TVAX Biomedical containing attenuated autologous cancer cells and activated autologous blood-derived T cells, developed through TVAX's immunotherapeutic cancer treatment platform. TVAX Immunotherapy is a proprietary method for treating cancer using many activated, genetically unique cancer-specific killer T cells. This vaccination generates an immune response in the patient, producing many cancer-specific T cells. The activated killer T cells trigger the body's immune system to destroy cancer cells, including cancer stem cells.

Get In-Depth Knowledge on Glioblastoma Multiforme Market Trends and Forecasts with DelveInsight @ Glioblastoma Multiforme Treatment Market- https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glioblastoma Multiforme Market Outlook
Glioblastoma is a malignant brain tumor that develops from a specific type of brain cell called an astrocyte. These cells nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Unfortunately, there is no cure for glioblastoma.

Scope of the Glioblastoma Multiforme Market Report
• Coverage- 7MM
• Glioblastoma Multiforme Companies- Genentech, Merck, Daiichi Sankyo, VBL Therapeutics, Diffusion Pharmaceuticals Bayer, MedImmune, DNAtrix, Chimerix, Karyopharm Therapeutics, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Kintara Therapeutics, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, Treovir, Istari Oncology, and others.
• Glioblastoma Multiforme Pipeline Therapies- Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, LAM561 (2-OHOA), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, VAL-083 (dianhydrogalactitol), MDNA55, Paxalisib (GDC-0084), Temferon, EO2401, INO-5401 + INO-9012 + LIBTAYO (cemiplimab), Delytact (Teserpaturev/DS-1647), TAFINLAR + MEKINIST, VBI-1901, and others.
• Glioblastoma Multiforme Market Dynamics: Glioblastoma Multiforme Market Drivers and Barriers

Unlock Strategic Insights with DelveInsight's Comprehensive Glioblastoma Multiforme Market Report @ Glioblastoma Multiforme Market Drivers and Barriers- https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. GBM Market Overview at a Glance
7. Disease Background and Overview: GBM
8. Treatment and Management
9. Epidemiology and Patient Population
10. Patient Journey
11. Key Endpoints
12. Marketed Drugs
13. Emerging Drugs
14. GBM: Seven Major Market Analysis
15. Unmet Needs
16. SWOT Analysis
17. KOL Views
18. Market Access and Reimbursement
18.4. Market Access and Reimbursement of GBM
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

List of Top Selling Market Research Reports in 2025

Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/underactive-bladder-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical sealant market - https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Ventral hernia market- https://www.delveinsight.com/report-store/hernia-repair-devices-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Trichotillomania market- https://www.delveinsight.com/sample-request/trichotillomania-ttm-market
Medical marijuana market- https://www.delveinsight.com/blog/medical-marijuana-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com

This release was published on openPR.